Peak 2017 memorabilia
Release time:
2020-08-14
Peak 2017 Major events
1# July
1# November 4 At the 6th member congress of Jinhua Federation of Industry and Commerce, Jiang Xiaomeng, chairman of the group company, was elected chairman of Jinhua Federation of Industry and Commerce and was commended as "2016 Xinyi Good Wushang.
September , the group company held the 2016 annual summary commendation conference.
2017 1 1 , with a time of five years.
September
March 28 , the board of directors of the group company deliberated and approved the phased investment proposal of Jianfeng pharmaceutical to Beijing huibaoyuan biotechnology co., ltd. the Jianfeng pharmaceutical industry will take Beijing huibaoyuan and its controlling subsidiary Guangxi huibaoyuan as the platform to jointly carry out new drug research and development, drug production and management and other businesses.
2013 and 2016 .
1 Class New Drug DPT (Deoxypodophyllotoxin) clinical application was approved by the State Food and Drug Administration.
21 , Yunnan Jianfeng Cement Company passed the review and acceptance of the second-level enterprise of safety production standardization.
June 25 , the 5th Member Congress and the 5th First Council of Zhejiang Building Materials Industry Association were held in Jinhua. Jiang Xiaomeng, chairman of the group company, was elected as the new president.
February
June 27 , Wu Guangjun, electrical director of Jinxi Factory of Pharmaceutical Company, was awarded the title of "Ba Wu Craftsman" at the first Ba Wu Craftsman Naming Conference in Jinhua City.
August
, 105 and ended on December 1, 106. 5# November 20 , Jinhua Federation of Trade Unions, Economic and Information Commission Working Committee and Jianfeng Group jointly sponsored the Jianfeng Group Staff Fun Games hosted by the Municipal Workers' Cultural Palace held in Jinhua Gymnasium.
July 6 January
day, peak pharmacy micro-mall began trial operation.
7
7 April
, the party Committee of the group company organized more than 80 party members of the in the gold enterprise to visit the former residence of Chen wangdao, the first generation of communist fighters in China and the first translator of the communist manifesto in Chinese, to remember the deeds of the revolutionary ancestors and relive their beliefs.
7 February 13 , the "Strategic Alliance for Technological Innovation in Plant Waste Reuse Industry" was formally established with Tianjin Jianfeng Natural Products Company as the chairman unit.
August 14 at the 11th Congress of Zhejiang Federation of Industry and Commerce, Chairman Jiang Xiaomeng was elected Vice President of Zhejiang Chamber of Commerce and Representative of the 12th Congress of the All-China Federation of Industry and Commerce.
8 July
8 January
, daye peak cement company desulfurization project started.
company video conference system upgrade completed.
March
daye peak won the title of "best integrity enterprise" in daye city. This is the city's first selection, recognition of integrity enterprises.
Daye Peak and Yunnan Peak both won the "Full Excellence Award" in the 16th National Cement Quality Index Test of "Hongchao Science and Technology Cup" in 2017 ".
10
10 September
, Yunnan Jianfeng Ton Packed Cement went abroad for the first time and was sent to Laos.
May 18 , the 19th National Congress of the Communist Party of China opened in Beijing. The Party Committee of the Group organized all senior executives, Party members and Party activists to watch the opening meeting.
19 , the company 2016
to 2017 9 November "three" cultivation project implementation work successfully passed the phased acceptance. 10 May 26 , the company organized fire training, fire evacuation and fire fighting drills in Peak Building.
Company ranked among the "2017 China Building Materials Enterprises
" in the industry joint selection organized by China Building Materials Federation, China Building Materials Enterprise Management Association, China Building Materials Industry Planning and Research Institute and other units ".
November 23 January Peak Pharmaceutical's key product Lestat (Amlodipine Aspartate Tablets) was named "2017 China's Most Growing Product" at the
National Pharmaceutical Economic Information Conference ".
February 16 , the company held a general meeting of shareholders to elect the board of directors and the board of supervisors. The new board of directors and the board of supervisors held their first meeting and elected Jiang Xiaomeng as the chairman of the new (10th) board of directors, Chen Tianci as the chairman of the new (9th) board of supervisors, the board of directors appointed the new management team and Yu Jianhong as the general manager of the company. November
12 to 18 , Yunnan Jianfeng Cement Company held the second "Jianfeng Cup" basketball invitational tournament, with representatives of 12
November 25 August 24 to 26 , Chairman Jiang Xiaomeng of the Group Company went to Beijing to attend the 12th National Congress of the China Federation of Industry and Commerce.
Peak Pharmaceutical renewed Wang Guangji, academician of the Chinese Academy of Engineering, as chief scientist. December February
Peak Pharmaceutical was recognized by the State Intellectual Property Office as the "National Intellectual Property Demonstration Enterprise" of
".
Company was rated as an advanced unit in Jinhua City.
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page